Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 9INDUSTRY 6NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 264Leukemia, Lymphocytic, Chronic, B-Cell 249Leukemia, Myeloid, Acute 236Leukemia 235Lymphoma 177Lymphoma, Non-Hodgkin 168Lymphoma, Follicular 154Burkitt Lymphoma 146Lymphoma, Large B-Cell, Diffuse 142Lymphoma, B-Cell, Marginal Zone 135Lymphoma, Mantle-Cell 133Lymphoma, Large-Cell, Immunoblastic 115Hodgkin Disease 109Myelodysplastic Syndromes 107Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 96Congenital Abnormalities 90Multiple Myeloma 86Lymphoma, T-Cell, Cutaneous 81Lymphoma, Large-Cell, Anaplastic 76Hematologic Neoplasms 75Leukemia, Myelomonocytic, Chronic 74Waldenstrom Macroglobulinemia 73Immunoblastic Lymphadenopathy 70Leukemia, Myelomonocytic, Acute 69Sezary Syndrome 68Mycosis Fungoides 68Blast Crisis 68Leukemia, Monocytic, Acute 62Myeloproliferative Disorders 61Leukemia, Myelogenous, Chronic, BCR-ABL Positive 61

Interventions

ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Paraproteinemias × Other hematologic neoplasm × Clear all
NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 11 charts
Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡